Stocks of Iovance Biotherapeutics Inc (NASDAQ:IOVA) traded higher last session on Wall Street, up 1.99% to $3.59.
IOVA stock price is now -35.39% away from the 50-day moving average and -56.80% away from the 200-day moving average. The market capitalization of the company currently stands at $1.18B.
With the price target of $17, UBS recently initiated with Buy rating for Iovance Biotherapeutics Inc (NASDAQ: IOVA). On July 29, 2024, Piper Sandler Downgraded its previous ‘Overweight’ rating to ‘Neutral’ on the stock reducing its target price from $19 to quote $10, while ‘Goldman’ rates the stock as ‘Buy’
In other news, Maynard Ryan D, Director sold 50,000 shares of the company’s stock on Nov 12 ’24. The stock was sold for $503,000 at an average price of $10.06. Upon completion of the transaction, the Director now directly owns 7,500 shares in the company, valued at $26925.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 12 ’24, Director Maynard Ryan D bought 50,000 shares of the business’s stock. A total of $503,104 was incurred on buying the stock at an average price of $10.06. A total of 19.01% of the company’s stock is owned by insiders.
During the past 12 months, Iovance Biotherapeutics Inc has had a low of $3.50 and a high of $15.90. As of last week, the company has a debt-to-equity ratio of 0.08, a current ratio of 3.74, and a quick ratio of 3.31. The fifty day moving average price for IOVA is $5.5562 and a two-hundred day moving average price translates $8.311 for the stock.
The latest earnings results from Iovance Biotherapeutics Inc (NASDAQ: IOVA) was released for 2024-12-31. The net profit margin was -226.84% and return on equity was -57.48% for IOVA. The company reported revenue of $73.69 million for the quarter, compared to $0.48 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 15189.21 percent.
